- Home
- / INVO Bioscience
INVO Bioscience
Stock Price
$0.8
2024-10-29
Market Capitalization
$3.3 M
2024-10-29
Revenue
$6.5 M
FY, 2024
INVO Bioscience Summary
Company Summary
- Overview
- INVO Bioscience is a medical device company focused on providing treatments for patients diagnosed with infertility. Its solution the INVO procedure is an in vivo method of vaginal incubation. The company also offers INVOcell, a medical device used in infertility treatment.
- Type
- Public
- Status
- Active
- Founded
- 2009
- Cybersecurity rating
Table of Contents
Key People
Kevin Doody, Medical Director and Director
Yve Lyppens, Director of Business Development Asia Pacific
Steven M. Shum, Chief Executive Officer
INVO Bioscience Financials
Summary Financials
- Revenue (Q3, 2025)
- $1.8M
- Net income (Q3, 2025)
- ($2.6M)
- Cash (Q3, 2025)
- $400.0K
- EBIT (Q3, 2025)
- ($1.6M)
- Enterprise value
- $6.1M